REGENXBIO, Inc. (RGNX)

Over the past six months, REGENXBIO's stock price has increased. As of October 21, 2025, the share price was $13.09, up from $9.59 on October 22, 2024, representing a 36.50% increase. Recent news includes participation in investor conferences, presenting interim data from the Phase II ALTITUDE® trial, and completing enrollment in pivotal trials for subretinal surabgene lomparvovec for wet AMD.

The provided information does not indicate any specific demand seasonality for REGENXBIO's gene therapy products and services. Demand is likely driven by disease prevalence, clinical trial progress, regulatory approvals, and market access rather than seasonal patterns. The company's revenue generation primarily comes from royalties and fees from research and development collaborations, which are not typically subject to seasonal fluctuations.

REGENXBIO Inc. is a clinical-stage biotechnology company focused on developing and commercializing gene therapy products, operating within the Healthcare sector and Biotechnology industry. Its core business revolves around its NAV® Technology Platform, which utilizes AAV vectors to deliver therapeutic genes to target cells. The company's pipeline includes gene therapy candidates such as RGX-314 for wet AMD, diabetic retinopathy, and other chronic retinal diseases, RGX-121 for MPS II, RGX-111 for MPS I, RGX-181 for CLN2, RGX-202 for Duchenne muscular dystrophy, RGX-381 for ocular manifestations of CLN2 disease, and RGX-501 for homozygous familial hypercholesterolemia.

REGENXBIO Inc. is headquartered in Rockville, Maryland, United States, and derives the majority of its revenue from the United States. The company is expanding its global presence through clinical trial sites located in North America, Europe, and Asia.

REGENXBIO is recognized as a pioneer in AAV gene therapy, distinguished by its proprietary NAV Technology Platform. The company's reputation is built on its focus on advancing gene therapy solutions for a wide range of genetic diseases and its commitment to improving lives through the curative potential of gene therapy. Its scientific advisory board guides its research and clinical trial strategies, further bolstering its scientific credibility.

REGENXBIO Inc. has significant institutional ownership, with 328 institutional owners and shareholders holding a total of 48,956,300 shares. Major institutional shareholders include BlackRock, Inc., Redmile Group, LLC, JPMorgan Chase & Co, Vanguard Group Inc, State Street Corp, Goldman Sachs Group Inc, and Geode Capital Management, Llc. Allan M. Fox, the Chairman of the Board, is a significant individual shareholder, owning 13.77% of the company's shares, and the company's CEO, Kenneth Mills, directly holds 0.6% of the total shares outstanding.